Form 8-K - Current report:
SEC Accession No. 0001193125-25-263543
Filing Date
2025-11-04
Accepted
2025-11-04 07:12:02
Documents
15
Period of Report
2025-11-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d17004d8k.htm   iXBRL 8-K 33610
2 EX-1.1 d17004dex11.htm EX-1.1 8433
3 EX-1.2 d17004dex12.htm EX-1.2 53172
4 EX-99.1 d17004dex991.htm EX-99.1 83789
  Complete submission text file 0001193125-25-263543.txt   329188

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA tsha-20251104.xsd EX-101.SCH 2843
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20251104_lab.xml EX-101.LAB 18736
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20251104_pre.xml EX-101.PRE 11702
18 EXTRACTED XBRL INSTANCE DOCUMENT d17004d8k_htm.xml XML 3803
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 251446430
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)